HTB homepage • Conference reports • Articles by subject • Subscribe 1 August 2017 Contents Hepatitis coinfection FDA approves sofosbuvir/velpatasvir/voxilaprevir (Vosevi) second-line DAA HCV treatment in the US in the US HTB homepage • Conference reports • Articles by subject • Subscribe
